1 Pharma Stock Poised for a Promising 2023
Following a year of solid growth in 2022, leading pharma company AstraZeneca’s (AZN) robust pipeline and recent launches look promising. Moreover, its strong fundamentals should enable the stock to deliver solid returns this year. So, AZN could be an ideal buy. Keep reading. Headquartered in Cambridge, United Kingdom, leading pharma company AstraZeneca PLC (AZN) surpassed…